01—Abstract
Summary
Summary of the 10-K filed February 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Edwards Lifesciences Corporation reported strong performance in its 2024 fiscal year, with net sales reaching $5.4 billiona, an increase of 8.6% year-over-year.
This growth was primarily driven by robust sales in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. The company also made significant strategic moves, including the sale of its Critical Care product group for $4.2 billionb and several key acquisitions aimed at strengthening its position in structural heart disease and expanding into heart failure management. Key financial highlights include a notable increase in net income and diluted earnings per share, supported by top-line growth and the positive impact of the Critical Care divestiture.
The company's commitment to innovation is evident in its continued investment in research and development, representing 19%c of net sales in 2024, with advancements in its TAVR and TMTT platforms. Edwards Lifesciences remains focused on its patient-centric strategy, aiming to transform care for those with structural heart disease and expanding its reach in interventional heart failure technologies.
02—Key points
Key Highlights
- Net sales increased by 8.6% to $5.4 billion, driven by TAVR and TMTT product growth.
- Successfully completed the sale of its Critical Care product group for $4.2 billion, refocusing the company on structural heart and heart failure.
- Acquired Endotronix, Inc., Innovalve Bio Medical Ltd., and JC Medical, Inc. to bolster its portfolio in heart failure management and transcatheter mitral replacement/regurgitation.
- Research and Development (R&D) investment increased by 9% year-over-year, representing 19% of net sales, underscoring commitment to innovation.
- Received FDA approval and launched the EVOQUE tricuspid valve replacement system in the U.S.
- Announced positive results from key clinical trials such as EARLY TAVR and TRISCEND II, supporting the adoption of early intervention and new therapies.
- Repurchased $1.2 billion of common stock in 2024, demonstrating a commitment to shareholder returns.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Edwards Lifesciences Corp kept $0.77.
- Revenue$5.44B100.0%
- Cost of revenue−$1.12B20.5%
- Gross profit$4.32B79.5%
- Operating costs−$2.94B54.1%
- Operating income$1.38B25.3%
- Interest, other & tax$2.79B51.3%
- Net income$4.17B76.7%
Where FY2024 revenue went
$5.44B- SG&A: $1.79B, 33% of revenue
- Operating income: $1.38B, 25% of revenue
- Cost of revenue: $1.12B, 21% of revenue
- R&D: $1.05B, 19% of revenue
- Other operating costs: $101.1M, 1.9% of revenue
Kept 25% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 28, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $5.44B$5.01B | +8.6% |
| Cost of Revenue | $1.12B$978.40M | +14.2% |
| Gross Profit | $4.32B$4.03B | +7.2% |
| R&D Expenses | $1.05B$962.90M | +9.4% |
| SG&A Expenses | $1.79B$1.58B | +13.1% |
| Operating Income | $1.38B$1.31B | +5.3% |
| Net Income | $4.17B$1.40B | +198.0% |
| EPS (Basic) | $6.98$2.31 | +202.2% |
| EPS (Diluted) | $6.97$2.30 | +203.0% |
| Shares Outstanding (Basic) | 597.70M606.70M | −1.5% |
| Shares Outstanding (Diluted) | 599.30M609.40M | −1.7% |
05—Questions
Frequently Asked Questions
What were the key drivers of Edwards Lifesciences' sales growth in 2024?
Edwards Lifesciences' net sales increased by 8.6% to $5.4 billion in 2024. The primary drivers of this growth were higher sales of Transcatheter Aortic Valve Replacement (TAVR) products, particularly the Edwards SAPIEN 3 Ultra RESILIA valve, and strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT), fueled by the PASCAL repair system and the launch of the EVOQUE tricuspid valve replacement system.
What is the strategic significance of divesting the Critical Care product group and the recent acquisitions?
The divestiture of the Critical Care product group for $4.2 billion allows Edwards Lifesciences to concentrate resources and investments on its core structural heart disease business, specifically TAVR and TMTT, and to accelerate its expansion into interventional heart failure technologies. The acquisitions of Endotronix, Innovalve Bio Medical, and JC Medical directly support this strategy by strengthening its offerings in heart failure management and advancing its transcatheter mitral valve technologies.
How is the company addressing potential risks related to litigation and regulatory compliance?
Edwards Lifesciences faces ongoing legal proceedings, including patent infringement claims and securities class actions, as detailed in the filing. The company is actively defending itself against these claims. Furthermore, the company operates in a highly regulated industry and is subject to stringent requirements from agencies like the FDA and EU MDR, which necessitate significant compliance efforts and carry potential risks of delays or penalties. The company proactively manages these risks through robust compliance programs and by investing in regulatory expertise.
What is the company's approach to research and development (R&D) and its impact on future growth?
Edwards Lifesciences demonstrated a strong commitment to R&D by investing 19% of its net sales in 2024, a 9% increase year-over-year. This investment is focused on developing innovative therapies for structural heart disease, including advancements in TAVR and TMTT, as well as exploring new interventional heart failure technologies. Key R&D achievements in 2024 include enrollment completion in pivotal trials and the launch of new products, which are expected to drive future growth and reinforce market leadership.
06—Continue